What can be considered as a major break through in over 11-month-long battle against the pandemic COVID-19, German Biotech firm, Pfizer Inc’s experimental COVID-19 vaccine, PFE.N has been found to be more than 90% effective based on its initial trial results.
The pandemic that showed its first signs in December at Wuhan, China last year December has so far claimed 12.69 lives and infected over 5.12 crore people worldwide.
Pfizer and German partner BioNTech SE 22UAy.F said they had found no serious safety concerns yet and expected to seek U.S. emergency use authorization this month, raising the chance of a regulatory decision as soon as December.
According to the company’s estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses by 2021, if permissions are granted.
“Today is a great day for science and humanity,” Pfizer Chief Executive Albert Bourla said.
He further added, the data milestone comes with “infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”
Experts said they wanted to see the full trial data, but the preliminary results looked encouraging.
However, experts feel there still are many questions, such as how effective the vaccine is by ethnicity or age and how long immunity may last, that needs to be answered eventually.
“But the bottom line is, as a vaccine it’s more than 90% effective, which is extraordinary,” top U.S. infectious diseases expert Dr. Anthony Fauci told CNN.
Pfizer expects to seek U.S. emergency use authorization for people aged between 16 to 85. To do so, it will need two months of follow-up safety data to assure no side effects crop up. That is expected to be available in the third week of November.